title: Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
abstract: Uveal melanoma is a rare but aggressive subtype of melanoma. Nearly 50% of patients will develop metastatic disease despite primary enucleation or radiation therapy. There is currently no standard of care therapy for metastatic uveal melanoma, and no therapy that has been shown to prolong overall survival. Uveal melanoma is characterized by activation of signaling pathways including the MAPK pathway and the PI3K/AKT pathway, among others, via mutations in the G-α-proteins GNAQ and GNA11. MEK inhibition with selumetinib has been evaluated as a therapeutic strategy in metastatic uveal melanoma. This review will discuss preclinical and clinical studies evaluating selumetinib in metastatic uveal melanoma, as well as potential future perspectives on MEK inhibition in the management of metastatic uveal melanoma.
authors.affiliation: Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
authors.forename: Kimberly M
authors.initials: KM
authors.lastname: Komatsubara
authors.affiliation: Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
authors.forename: Daniel K
authors.initials: DK
authors.lastname: Manson
authors.affiliation: Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Carvajal
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D014604:Uveal Neoplasms / Q000188:drug therapy*; D000098943:Uveal Melanoma
chemical_list: C517975:AZD 6244; D000970:Antineoplastic Agents; D001562:Benzimidazoles
keywords: MEK inhibitor; selumetininb; uveal melanoma